Monthly Archives: August 2017

The Haters Are Wrong: Sublime’s 40oz. to Freedom Is a Long Beach Classic – L.A. Weekly

Posted: August 2, 2017 at 9:10 am

Wednesday, August 2, 2017 at 5 a.m.

In the quarter century since its release, Sublimes 40oz. to Freedom has soundtracked approximately 1.2 million backyard house parties, 2.7 million hotbox sessions and the glorious decimation of 124 trillion brain cells.

The official debut from the sun-fried Long Beach fusionists is implicitly responsible for weeds legalization in California, and its title track has kept the malt liquor business afloat more than any gimmicky advertisement ever could. It might be the most alternately loved and loathed masterpiece in music history.

This is where I tell you the haters are wrong. To dismiss 40oz. to Freedom is to deny the cultural ferment of Southern California itself; its conflating the flip-flops and gravity-bong clichs of fans with the brilliant syncretism of the band itself. To indict Sublime is to diss Long Beach, among the most diverse cities in the country, where the bands lead singer, Bradley Nowell, famously attended Polytechnic High around the same time as Snoop Dogg and Cameron Diaz.

Thats no coincidence. Sublime created platonic Southern California house-party music by appealing to everyone passing the J, from blond surfers and magnet-school actresses to Long Beach Crips and the first-generation progeny of Mexican, Cambodian and Caribbean immigrants.

The solution was to throw in everything, a risky choice that invariably fails for everyone but Sublime. During an atomized era when skaters and surfers, punks and hip-hop heads, reggae stoners, jam wookies and Spanish-language pop all ostensibly existed in their own universes, the Long Beach trio fostered a harmonious peace.

40oz. to Freedom starts with a Minutemen sample and quickly veers into an absurd, slanged-out, bilingual narrative about picking up a girl named Ramona who wants to go to a house party. Smoke Two Joints samples Eazy-E and Just Ice as part of a scratched hook. Theres a tribute song to KRS-One and covers of The Melodians, Bad Religion and the Grateful Dead.

These arent token gestures of eclecticism but the innate obsessions of a troubled yet deceptively intelligent lead singer with a genius for songcraft. Before dropping out a semester short of his degree, Nowell studied finance at UC Santa Cruz and Cal State Long Beach.

Singing in Spanish wasnt merely a nod at inclusiveness it reflected Nowells years spent studying the language, trips to Central America and growing up around Latinos. The dedication to the frontman of Boogie Down Productions wasnt some ironic gag but testament to a deep love and understanding of hip-hop culture, down to the Dust Brotherslike bricolage of psychedelic samples that permeate the album.

Nowell wasnt a Ras Trent but someone profoundly invested in reggae and dub. An inscrutable artist disguised as a drug-addled surfer bro, a seeker with a bizarre sense of humor and a ravenous appetite for all strains of sound.

In the abridged list of inspirations shouted out on the albums finale, he thanks Miles Davis, Bob Marley, Jimi Hendrix, Eek-A-Mouse, Crass, Fugazi, Butthole Surfers, Frank Zappa and Meat Puppets. You hear them all in 40oz. to Freedom, cloaked in goofy weed jokes, warped odes to psychic darkness, safe-sex testimonials rapped in Spanish and a particularly infamous antidate rape song. The latter has aged poorly in the context of contemporary mores, but it still attacked sexual assault at a time when most male singers stayed quiet on the topic.

If 40oz. to Freedom revels in its careening, narcotic whimsy, thats partially why its stood the test of time. At its core, music is utilitarian, and Sublime reached a universality of experience that cant become obsolete. As long as there are house parties to crash, 40s to sip and joints to smoke, there is this record. Besides, you have brain cells to spare.

An L.A. native, Jeff Weiss edits Passion of the Weiss and hosts the Bizarre Ride show on RBMA Radio. Follow him on Twitter @passionweiss.

More from Jeff Weiss: Prince's Friend and Former Bandmate Cymone Is Keeping the Purple One's Spirit Alive Kendrick Lamar's DAMN. Confirms It: This Is the Golden Age for L.A. Hip-Hop Why Elliott Smith's Either/Or Is My "Break Glass in Case of Existential Crisis" Album

Continue reading here:

The Haters Are Wrong: Sublime's 40oz. to Freedom Is a Long Beach Classic - L.A. Weekly

Posted in Freedom | Comments Off on The Haters Are Wrong: Sublime’s 40oz. to Freedom Is a Long Beach Classic – L.A. Weekly

Freedom bats fall silent, team manages just three hits in series-opening road loss to Rascals – User-generated content (press release) (registration)

Posted: at 9:10 am

The Florence Freedom, presented by Titan Mechanical Solutions, saw their bats fall silent Tuesday night at CarShield Field, falling in the series opener to the River City Rascals, 9-1.

The Freedom (42-25) managed just three hits in the game, each of which came off Rascals (37-31) starter Lucas Laster (1-1), who battled bouts of wildness en route to walking five but lasted six innings.

After a Paul Kronenfeld RBI-single off Braulio Torres-Perez (2-1) in the bottom of the first inning, the Freedom tied the score in the top of the second. Collins Cuthrell worked a leadoff walk, took third on a Jordan Brower single and score on a groundout to second by Andrew Godbold. But Clint Freeman homered to right-center in the bottom half to put River City back in the lead for good.

Torres-Perez would go on to strike out eight, but also issued a season-high six walks. The left-handers only scoreless inning was the fourth, in which he overcame a leadoff walk by inducing two fielders choice grounders and caught Mike Jurgella breaking early from first base on an attempted steal.

Josh Silver hit two doubles while he and Josh Ludy each drove in two runs for River City, while Freeman collected three hits to lead the Rascals, who would also score two runs off reliever Jack Fowler in the eighth, following a scoreless seventh by Enrique Zamora.

Keivan Berges provided a defensive highlight for Florence in the sixth, throwing out Jurgella at the plate from left field on an attempted tag up from third on a fly ball by Silver.

Matt Chavarria earned the save for River City, allowing only a walk to Garrett Vail over the final three innings.

The four-game series continues with a doubleheader Wednesday, with the first game scheduled to begin at 5:05 p.m. Newly-acquired right-hander Steve Hagen (4-4) will start the first game for the Freedom against River City left-hander Dan Ludwig (5-2), while right-hander Cody Gray (7-2) will start game two for Florence against Rascals righty Reese Gregory (6-4).

The Florence Freedom are members of the independent Frontier League and play all home games at UC Health Stadium located at 7950 Freedom Way in Florence, KY.The Freedom can be found online at FlorenceFreedom.com, or by phone at 859-594-4487.

Original post:

Freedom bats fall silent, team manages just three hits in series-opening road loss to Rascals - User-generated content (press release) (registration)

Posted in Freedom | Comments Off on Freedom bats fall silent, team manages just three hits in series-opening road loss to Rascals – User-generated content (press release) (registration)

Conservatives’ ‘power of no’ stifles Republican agenda – News & Observer

Posted: at 9:10 am

Conservatives' 'power of no' stifles Republican agenda
News & Observer
The power of the House Freedom Caucus, says its leader, lies in the power of negation." It's the power of 'no,'" said Rep. Mark Meadows, R-N.C., whose 40-member group of diehard conservatives in the House has been responsible for killing one ...

and more »

See original here:

Conservatives' 'power of no' stifles Republican agenda - News & Observer

Posted in Freedom | Comments Off on Conservatives’ ‘power of no’ stifles Republican agenda – News & Observer

USDA creating better quality of life, safer environment through technology transfer – FederalNewsRadio.com

Posted: at 9:10 am

What do fluorescent lights that scan for Salmonella, remote sensors for testing bridge stability and a tool to identify bee mites have in common?

Theyre part of the latest crop of innovative ideas that make up the244 new inventions and 109 patent applications included in the Agriculture Departmentsannual report on technology transfer.

The report itself tries to compile new inventions, patents, technology breakthroughs, new methodologies; really the kinds of collaborations that USDA science and technology folks have with the private sector through special agreements, said acting USDA Undersecretary Ann Bartuska. So you have an incredible array of things that are in the annual report. My favorite ones happen to be the things that clearly demonstrate breakthroughs and innovations. In fact, they really do represent the range of work that happens at the 16 agencies that comprise USDA.

The report started being published within the last 20 years. Each year, theres a call for what everybody throughout the USDAand its components is working on.

Your opinion matters. Take Market Connections survey about how you consume media.

It covers the gamut of agreements like CRADAs, which are cooperative research and development agreements with the private sector. It includes patents. It includes licenses. It includes new exploratory work thats happening, said Bartuska, whois also serving asacting chief scientist for research, education and economics at USDA.So its really quite diverse in what its capturing. There is in the report tables that capture the data in those categories by agency, and then we roll it all up to one for the department.

Bartuska said this years report is pretty consistent with past years numbers of patents and inventions, though the output can be impacted by technological breakthroughs. In fiscal 2015, the report included 222 new inventions and 125 new patent applications.

For example, gene sequencing has created a whole new set of processes and products and subsequent opportunities for research and development, Bartuska said.

The outcomes that especially our intramural agencies Agricultural Research Service, Animal and Plant Health Inspection Service (APHIS), the Forest Service I think the work that they have done, the production of new things, has beenpretty constant over time, with some blips, Bartuska said. The genomic sequencing probably is one area. Theres been some advances inpest protection and quarantine matters, that really track where theyve had infestations, so you might be able to follow some increases and outcomesfollowing a particular pest outbreak, and then it goes back. Theres a lot of interest in disease transmission right now. If I look at that report, theres a lot on mosquitoes and transmissions.

That includes the enhancement of clothing worn by Marines to better prevent bug bites.

Bartuska said if she had to look to future reports, she would expect to see an increase in water use and drought response.

New bill would loosen restrictions on TSP withdrawals

Were really interested in reducing the amount of water used by Agriculture and being more responsible in the water that we use, Bartuska said.

She said sensor technology and the use of aerial vehicles [drones], and how those technologies can be more effective and efficient, is another area where future technology transfer reports mightshow an increased interest.

Effectiveness and efficiency are things USDA always has in mind, especially when it comes to a return on investment for taxpayers, Bartuska said.

One hundred percent of the people use our product because we produce food, Bartuska said. And so wetouch everybody, but to do it in a sustainable way, to be able to meet other peoples values on the environment and water quality, were very conscious of that. A lot of this return on investment is how you do work more efficiently, more effectively. And again, get a lot of benefit by that dollar that weve been investing.

Bartuska said according to USDA math, for every dollar invested in research and development, $20 is returned to taxpayers.

One example in the report that highlights USDAs mission is an anti-cancer drug developed by Penn State University researchers. The drug comes from parts of Omega-3 fatty acids.

The connection back to USDA is that other than not only funding good science,but Omega-3s are found in agricultural and aquacultural products, so youre extracting from one of our products into something that would then benefit human health, Bartuska said. It really does reflect that Agriculture is in part about farming, but Agriculture is so much about all kinds of food technology that we have, diseases; the diversity, again, of activities under USDA is incredibly broad.

The report also highlights the work USDA does with universities, the private sector and other agencies, Bartuska said.

Agreements with the private sector can come in the form of cooperative research and development agreements, and at some point, those products can be moved into the private sector.

In some cases, the patent would be held by us and they get exclusive license on the product, but it allows us then to form and both mutually invest in an outcome, Bartuska said. So weve really been trying to promote especially when we see the potential for a particular line of research to become a commercial activity, to build these private sector partnerships.

The report also complements the administrations Made In America, campaign, through contributing to job growth and supporting new business, especially in rural areas, Bartuska said.

Allthose products that you see in the technology transfer report, we can see them as helping to contribute to this overall Made In America process, Bartuska said. Technology transfer is all about development of a research product and then moving it to somebody to use it. It is as fine to me thata CEO of a company uses something as you [would] in your home, because hopefully what youre using is creating a better quality of life, a safer environment, a better use of resources so that were reducing waste, were reducing water consumption. So all of those things really add upto the value of what our research products can do.

Read the rest here:

USDA creating better quality of life, safer environment through technology transfer - FederalNewsRadio.com

Posted in Technology | Comments Off on USDA creating better quality of life, safer environment through technology transfer – FederalNewsRadio.com

Pharmaceutical Brands Can Use Programmatic Technology, Too – eMarketer

Posted: at 9:10 am

Jack Hogan CTO Lifescript

For pharmaceutical companies, deploying programmatic technology is a sticky subject. Because of strict privacy and patient protection laws, pharma companies are limited in how they can target individual consumers, which makes programmatic advertising more of a guessing game. But that doesnt mean it cant be done. Jack Hogan, CTO at medical publisher Lifescript, spoke with eMarketers Maria Minsker about how pharma companies can use publishers data to leverage programmatic technology.

eMarketer: How can medical publishers create proxy audiences to power programmatic technology for pharma brands?

Jack Hogan: Medical publishers have vast audiences of opt-in consumers with targetable IDs and declared health interests. Were talking about first-party data, not third-party health and medical data, which is inaccurate 50% of the time. By decoupling that first-party, declared health data from any private information, publishers enable brands to reach desired audiences with specific medical interests across the entire ad ecosystemwithout breaking any HIPAA rules.

Publishers are able to create segments of users interested in certain conditions, and feed these audience sets to pharma companies.

eMarketer: How does this make it possible for pharmaceutical companies to leverage programmatic advertising technology?

Hogan: While the guidelines for HIPAA are very stringent and strict when it comes to the type of data that can be accessed and shared, medical publishers typically dont touch any medical records or confidential medical data. Rather, publishers have access to declared interest in specific conditions or symptoms, which falls under other guidelines. As a result, publishers are able to create segments of users interested in certain conditions, and feed these audience sets to pharma companies through programmatic pipelines for ad targeting.

Plus, once a publisher zeros in on a users interests and pinpoints that users identity using a primary identifier such as an email address, that anonymized identity can then be extended to a mobile device for programmatic advertising via mobile as well.

eMarketer: Can you share an example of how a brand might work with a publisher to target a specific audience segment using programmatic technology?

Hogan: Lets say a statin drug manufacturer is looking to target people who have high cholesterol with a marketing campaign. A publisher can create a segment of people who have self-identified as showing interest in this topic while engaging with the publishers site. The publisher can then make that segment available to the advertiser through a programmatic pipeline, enabling them to work with their technology vendors to target that segment through programmatic display, video or mobile advertising.

There are some marketers in the space who dont understand the marketing technology requirements for handling private data.

eMarketer: Are enough pharmaceutical marketers taking advantage of programmatic advertising, or are they missing an opportunity when it comes to health data?

Hogan: There are some marketers in the space who dont understand the marketing technology requirements for handling private data. For example, all user data should be de-identified, and not tied back to an individual. Personal health data like that should not be used in any marketing or advertising efforts. Marketers should be using smart tools that can decouple data from individuals identifiers, starting at the point of opt-in through collection and use.

See the article here:

Pharmaceutical Brands Can Use Programmatic Technology, Too - eMarketer

Posted in Technology | Comments Off on Pharmaceutical Brands Can Use Programmatic Technology, Too – eMarketer

Asian Technology Stocks Just Hit 17-year Peaks – Fortune

Posted: at 9:10 am

LONDON, Aug 2Asian technology stocks hit 17-year peaks and Wall Street's Dow index looked set to break 22,000 points later on Wednesday, as blockbuster earnings from Apple rippled out to component makers globally.

Shares in the world's most valuable company surged 6% after-hours to a record of more than $159 each, taking its market capitalization above $830 billion.

That should help carry the Dow through the 22,000 mark when trading resumes in New York. E-Mini futures for the Dow were up 0.2 percent despite a lower Europe as disappointing results from Societe Generale and Commerzbank weighed on the bank stocks.

Apple reported better-than-expected iPhone sales , revenue, and earnings per share and signaled its upcoming 10th-anniversary phone is on schedule.

It helped dispel one of the few nagging doubts of the corporate earnings season so farthat Amazons lackluster results last week might have revealed some tiredness among the giant U.S. tech and internet stocks that have been driving the stock market rally all year.

"It is all about Apple," said Naeem Aslam chief market analyst at Think Markets. "The firm comfortably topped its forecast and produced stellar numbers for its revenue and profit."

Among Asia's Apple suppliers, LG Innnotek jumped 10 percent and SK Hynix, the world's second-biggest memory chip maker, rose 3.8 percent.

Murata Manufacturing firmed 4.9 percent and Taiyo Yuden 4.4 percent, helping Tokyo's Nikkei up 0.47 percent.

The MSCI tech index for Asia also climbed 0.9 percent to ground not trod since early 2000, bringing its gains for the year to a heady 40 percent.

Those gains balanced losses in basic materials and energy to leave MSCI's broadest index of Asia-Pacific shares outside Japan steady near its highest since late 2007.

There was a note of caution over reports that U.S. President Donald Trump was close to a decision on how to respond to what he considers China's unfair trade practices.

Tepid U.S. inflation along with political turmoil in Washington has lessened the possibility of another Federal Reserve rate hike this year, lowering bond yields across the globe.

Improving data in other major economies has also served to push the greenback down nearly 11 percent from January peaks, benefiting commodities and emerging markets.

A swathe of manufacturing surveys (PMIs) out on Tuesday had underlined how the improvement in activity had broadened out from the United States to Asia and Europe.

Alan Ruskin, head of G10 forex at Deutsche Bank, noted the top five PMIs were all Northern European economies and every index in Europe was now in expansionary territory above 50.

"That will do nothing to hurt ebullient global risk appetite," said Ruskin. "This phase of the risk rally is based on growth data, but even more on subdued inflation measures."

MSCI's gauge of stocks across the globe was just below an all-time peak.

On Wall Street later electric car maker Tesla, gadget firm Fitbit and insurance provider AIG will report results.

In currency markets, the dollar index was stuck at just under 93, after touching 92.777, the lowest since early May 2016. It was aided by gains on a softer yen which saw it creep to 110.80.

Yet the euro also benefited from buying against the yen , reaching its highest since February last year. It nudged up against the dollar and Swiss Franc too, briefly striking new 2-1/2-year highs against both at $1.1846 and 1.1468 francs per euro respectively.

Euro zone June producer price inflation data helped it on its way as it topped analysts' forecasts. There was a slowdown in the pace overall, but it bolstered bets that the European Central Bank could soon start winding down its more than 2-trillion-euro stimulus program.

"The ECB is going to be the central bank to watch for the rest of the year," said JP Morgan Asset Management global market strategist Alex Dryden.

"We think they are going to take 9-12 months to get out of the market but that is a big question ... it could even be six months," he added.

Bond markets were largely quiet, with the premiums investors demand to hold South European government debt over the German equivalent close to their lowest levels in weeks and both 2- and 10-year U.S. Treasury yields barely budged.

In emerging markets, MSCI's EM stocks index was near a three-year high. India's central bank became the first in Asia to cut interest rates this year, while Venezuela's bonds continued to slid amid rising political tensions there around President Nicolas Maduro.

Oil prices were under pressure again too amid rising U.S. fuel inventories and as major world producers kept pumping, causing investors to worry that several weeks of steady gains had pushed the rally too far.

Brent crude eased to $51.80 a barrel, while U.S. crude lost 8 cents to $49.07.

(Additional reporting by Wayne Cole in Sydney; Editing by Andrew Heavens)

Read more from the original source:

Asian Technology Stocks Just Hit 17-year Peaks - Fortune

Posted in Technology | Comments Off on Asian Technology Stocks Just Hit 17-year Peaks – Fortune

Teachers embracing technology in the classroom – KRIS Corpus Christi News

Posted: at 9:10 am

CORPUS CHRISTI -

Teachers from area districts are turning to technology to make learning activities more exciting for students and staff alike. Instructional Technology Specialist Cary Perales says, it's all for the third annual "Tech 2 Teach" conference held at Veterans Memorial High School.

"We have teachers that're on their break coming in to learn something to bring to their classroom to teach at a higher level," Teacher, Denis Wisner said.

Wisner is just one of nearly a thousand teachers trying to better their ability to educate, ahead of the new school year.

"Really it's to let our teachers get fired up about going back into the classroom and teaching our students those 21st century skills sets that they need," Perales said.

She adds, that the conference considers multiple ways of learning and bringing staff together.

"Getting to network with other teachers, they're getting to see all kinds of sessions integrating technology in the classroom."

Teachers like Emily Schellinger and Jenifer Martinez say, while technology is seeming taking over, some still like the old fashioned way of hands-on learning. However, students are still encourage to B.Y.O.D.

"It's very important for the students to come into the classroom and use their devices, here at Veterans we have BYOD, which is bring your own device and whether it's a phone or chrome book or a laptop the kids are encouraged to use it," Martinez said.

Overall, the goal is to keep the attention of easily distracted students, focused on fun, interactive learning tools.

More information: https://www.tcea.org/event/area-2-corpus-christi-technology-conference-tech2teach/

Read this article:

Teachers embracing technology in the classroom - KRIS Corpus Christi News

Posted in Technology | Comments Off on Teachers embracing technology in the classroom – KRIS Corpus Christi News

A Better, Safer Battery Could Be Coming to a Laptop Near You – New York Times

Posted: at 9:10 am

Ionic said it had developed prototypes of a rechargeable alkaline battery that can be made using continuous manufacturing processes similar to the making of plastic wrap. So far, the company, which is backed by William Joy, a pioneering Silicon Valley computer designer, has demonstrated up to 400 recharge cycles for its prototypes. Ionic executives say they believe they will be able to triple that.

The alkaline batteries that Ionic has developed would initially be heavier than todays lithium-ion batteries, said Mike Zimmerman, a materials scientist who is the founder and chief executive of Ionic. But the new batteries would more than compensate for that handicap with their cost advantage and, in time, their ability to store more energy.

There are other advantages besides cost and safety. Lithium-ion batteries rely on cobalt, and using that element comes with a human cost. Cobalt mines in Africa, for example, have been accused of using child labor while leaving behind a toxic mess.

Alkaline batteries, on the other hand, use relatively abundant zinc and manganese. Ionic can help us get lithium-ion past cobalt and completely eliminate it with alkaline, said Mr. Joy, who is a member of Ionics board.

He also said that the company had made progress toward an alkaline battery design that would replace zinc with more affordable aluminum. In the past, aluminum has not been usable because of issues like corrosion. Alkaline batteries based on aluminum would potentially weigh less than lithium-ion batteries and would be even cheaper to produce than todays alkaline designs.

Ionic will make its announcement in Colorado at a conference for the 35th anniversary of the Rocky Mountain Institute, a sustainable-energy research group founded by the physicist and environmentalist Amory Lovins and Hunter Lovins, his former wife.

They started with a very sensible set of criteria, Dr. Lovins said of Ionic. They use an unusual electrolyte to come up with a battery that uses common cheap materials and is benign.

But he added a note of caution: Batteries are very difficult and I want to see what they have and what can be measured and proven and whether it will get to market.

Technological progress in battery technology has been glacial compared with the exponential advances in processing speed and data storage capacity that have been staples of Silicon Valleys growth. In the last 150 years, only a handful of rechargeable battery chemistries have reached mass adoption.

Tesla, in partnership with Panasonic, is building a factory in Nevada with the intent of greatly expanding capacity to make lithium-ion batteries and lower production costs. Tesla officials said they wanted to create enough capacity to produce batteries for 1.5 million cars a year.

There is growing interest in pursuing such so-called solid-state battery technologies for both consumer and transportation applications. Last fall, the United States Department of Energys agency for supporting research in next-generation energy technology announced 16 research awards aimed at accelerating development of solid battery technologies, including a $3 million contract to Ionic Materials. The company said it had signed several licensing deals to produce commercial versions of its design, but it would not identify its partners.

The United States Advanced Battery Consortium, an auto industry group, wants to greatly reduce the cost of lithium-ion production. Analysts, however, say they believe the new facilities and technology from auto and battery manufacturers will help bring costs down, but still fall short of industry goals.

In contrast, Ionic executives said they had found a way to achieve energy production costs that would be less than a fifth of the auto consortiums target.

Bloomberg New Energy Finance, an energy research group, has forecast that mass-market adoption of electric vehicles will not occur until operating costs fall to match those of internal combustion engines. That is expected to happen in 2025, according to the group.

In December, Ionic Materials also described a solid material it said would improve the safety of existing lithium-ion batteries. The company has demonstrated the batteries resistance to catching fire or exploding by driving nails through them and even shooting them with bullets.

A version of this article appears in print on August 2, 2017, on Page B2 of the New York edition with the headline: Massachusetts Start-Up Trumpets Advance in Battery Capacity.

Read more from the original source:

A Better, Safer Battery Could Be Coming to a Laptop Near You - New York Times

Posted in Technology | Comments Off on A Better, Safer Battery Could Be Coming to a Laptop Near You – New York Times

Geron: SLOW Progress – Seeking Alpha

Posted: at 9:10 am

Introduction

From the formation of their collaboration in November 2014, Geron (NASDAQ:GERN) and Janssen, Johnson and Johnson's (JNJ) pharmaceutical arm have moved steadily forward in their efforts to prove the beneficial impact of imetelstat as a critical lifesaving therapy in the battle against certain cancers. Step by methodical step, they have advanced their understanding of imetelstats detailed clinical merits. Two clinical trials are gathering and assessing necessary data and have undergone formal clinical reviews.

Today they announced another advance. Insofar as it involves still more data collection, the market is showing frustration with the pace of progress. Shareholders can only wince and go forward. Todays announcement constitutes progress, albeit progress of the frustrating type for those impatient for final resolution.

Last night's press release from Geron, followed by this morning's conference call, provided new data points to consider in the lingering imetelstat saga. The conclusion I drew from the carefully scripted presentations was that all's well for those who have plenty of time and are willing to wait patiently while this multipart drama unfolds on its own time schedule.

My initial introduction to this latest bit of news was quite disconcerting. This morning I was checking out the stocks I follow and saw that Geron had taken a big hit. Then I saw a SA news headline, "Geron down 13% in early trading on extended timeline for imetelstat study, risk that Janssen will bail".

Oh no, I thought; the worst is happening. Then I realized after reading the release that this was nothing more than business as usual in the imetlstat world. Any statement about Janssen potentially bailing was mere surplusage. As is true in most, if not all such deals, the big dog has a retained right to bail. It is a background fact, akin to gravity...no need to keep repeating it, particularly in a news item. I guess the point that gave it piquancy was the stock price drop, suggesting something more was afoot. Not so.

Let me address the basics of the announcement and its significance as I see it.

First, the Imerge trial addresses patients with low-to-intermediate risk myelodysplastic syndromes (MDS) who failed to respond to prior treatment with an erythropoiesis-stimulating agent.

Janssen has analyzed data from the Imerge trial and has determined that a subset of 13 patients show positive results at a higher rate than the remaining group of patients. These 13 patients share the commonality that they had not received prior treatment from "... a hypomethylating agent (HMA) or lenalidomide".

Janssen further determined that it should enroll an additional cohort of 20 patients to bring this subset of patients to 30, the number that it considers sufficient for its next analysis.

Rather than being negative or neutral, I consider this decision to be on the whole positive. It shows that Janssen is actively interested and engaged with the imetelstat data.

It also shows that this is going to be a lengthy process. The timing is uncertain but the press release states that active recruitment will begin in Q4, 2017. Certainly the work of recruiting, enrolling, processing and then analyzing data from 20 additional patients implies a considerable time lag.

In the written press release Geron states:

Detailed results for the original 32 patients in Part 1 of IMerge, including key secondary endpoints of hematologic improvement and rate of RBC-TI lasting at least 24 weeks, as well as duration of response and detailed safety information, will be submitted for presentation at a major medical conference. [Emphasis added]

The more Janssen interacts with imetelstat in the public sphere, the more encouraged I become that it will proceed to bring the therapy to market. Certainly its previous announcement of imetelstat as future blockbuster in its pipeline was a big positive indication. I take its intention to present Imerge results at a major medical conference in the same vein.

Janssen's Phase 2 IMbark trial, assessing imetelstat in patients with treatment-resistant intermediate/high risk myelofibrosis (MF) is on an entirely different track.

The IMbark trial will continue without modification. According to the press release:

Janssen will conduct an internal data review in Q1 2018 to enable a protocol amendment to allow long-term treatment and follow-up. Janssen will notify Geron earlier, probably in Q4, whether it intends to pursue development of imetelstat for any indication after a primary data analysis is done on IMbark (should start no later than the end of Q3)

As I see this, today's CC simply confirms the ongoing process to which Janssen has committed itself. As far as any tell on the efficacy of imetelstat, it has to be more on the positive side than the negative.

Although, when one looks at a five day chart of Geron's stock, it doesn't look positive.

GERN Price data by YCharts

What caused this violent stock reaction? I suspect it was impatience.

For those who are timing imetelstat's progress towards continuation by Janssen and ultimately FDA approval, today was something of a disappointment. Optimists have hoped that Janssen would take its next big step forward by issuing a continuation decision under its Geron collaboration agreement sometime in 2017 or early in 2018.

The following language from its press release suggests to me that Q3, 2018 is a more likely target date:

Continuation Decision

The Joint Steering Committee has agreed that the timing of the protocol-specified primary analysis for IMbark will begin upon the earlier of either a pre-specified number of deaths occurring in the trial or the end of the third quarter of 2018. Following completion of this primary analysis, which includes an assessment of potential survival benefit associated with imetelstat treatment, Janssen will notify Geron whether it elects to maintain the license rights and continue the development of imetelstat in any indication, i.e., the Continuation Decision.

Generally my own optimism for Geron's imetelstat prospects focuses more on the likelihood that Janssen proceed, rather than any expectation that it do so on an expedited basis. However, today's drop suggests that I may be in the minority on that score.

Geron had cash and equivalents of $121MM according to its Q1, 2017 10-Q. This was stated as sufficient for expected needs for at least one year. However, insofar as net cash expended during Q1, 2017 was <$8MM, Geron should not face a cash crunch if indeed Janssen waits to issue a continuation decision until 2018.

At the close of Geron's 8/1/2017 call, Geron announced that because of the proximity of its upcoming earnings release, it would not do an earnings CC this quarter. Rather, it said it would issue its earnings press release. Geron will next address investors at its presentation to the Cantor Fitzgerald Healthcare Conference taking place September 25-27, 2017.

Geron is soldiering boldly ahead as it works to bring the development of imetelstat to fruition. There are no guarantees in this drug approval business. However, Geron has managed to put itself on a path where it has reasonable prospects for a highly remunerative future.

Geron offers a binary bet on its imetelstat cancer therapy. Although I know from researching Geron articles that it has other irons in the fire, I also know these other irons have no current impact on Geron's stock price.

Today's announcement seems to have disturbed the market. I submit that it should not have done so. When Johnson and Johnson boasted about imetelstat's future prospects, it was referring to the year 2021.

Anyone who has counted on this playing out as near term story has been fooling themselves. Geron appears to have the cash resources to follow this to its conclusion. Investors in Geron should likewise consider that they are in it for the long haul.

Disclosure: I am/we are long GERN.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Read the original:

Geron: SLOW Progress - Seeking Alpha

Posted in Progress | Comments Off on Geron: SLOW Progress – Seeking Alpha

Progress Releases Kendo UI Builder 2.0, Delivering the New Face of OpenEdge Web Experience – Business Wire (press release)

Posted: at 9:10 am

BEDFORD, Mass.--(BUSINESS WIRE)--Progress (NASDAQ: PRGS) today announced the latest version of Progress Kendo UI Builder, an industry-leading responsive web UI toolkit for rapidly delivering beautiful and intuitive web experiences. The new release introduces browser compatibility with Electron Shell, an extended library of built-in templates, the ability to customize screens with Blank View and enhanced data connectivity.

Today, the ultimate success of a business application depends on the availability of an engaging user experience. While reliability and scalability remain the backbone of superb performance, the look and feel of an application is vital for attracting and retaining users, said John Ainsworth, SVP, Core Products, Progress. With the latest version of Progress Kendo UI Builder toolkit, our partners and customers can quickly and cost-effectively enhance their Progress OpenEdge applications using an extended library of UI components and data connectivity to better optimize development efforts.

New features in Progress Kendo UI Builder 2.0 toolkit include:

In todays digital world, the ability to quickly develop software gives organizations a competitive advantage. With Progress Kendo UI Builder toolkit, weve significantly accelerated the development time of our new web-based application, TWIN360, by leveraging its ready, pre-built UI components, said Magnus Svensson of CGI, a global information technology and business process services provider. Progress Kendo UI Builder toolkit enabled us to easily create beautiful and personalized user interactions across all channels and devices and, as a result, to ensure excellent customer satisfaction.

Progress Kendo UI Builder toolkit enables developers to define the layout and content of their web apps with easy to use, pre-built and pre-tested visual components. Based upon the popular Progress Kendo UI framework and built to run on industry-standard technologies such as Angular, HTML, CSS and JavaScript, Progress Kendo UI Builder toolkit minimizes development time.

For more details about the latest release of Progress Kendo UI Builder toolkit, and to download a free trial, please visit https://www.progress.com/openedge/components/kendo-ui-builder or watch webinar.

Additional Resources

About Progress Progress (NASDAQ: PRGS) offers the leading platform for developing and deploying mission-critical business applications. Progress empowers enterprises and ISVs to build and deliver cognitive-first applications, that harness big data to derive business insights and competitive advantage. Progress offers leading technologies for easily building powerful user interfaces across any type of device, a reliable, scalable and secure backend platform to deploy modern applications, leading data connectivity to all sources, and award-winning predictive analytics that brings the power of machine learning to any organization. Over 1700 independent software vendors, 80,000 enterprise customers, and 2 million developers rely on Progress to power their applications. Learn about Progress atwww.progress.comor +1-800-477-6473.

Progress, OpenEdge, and Kendo UI are a trademarks or registered trademarks ofProgress Software Corporationand/or one of its subsidiaries or affiliates in the US and other countries. Any other trademarks contained herein are the property of their respective owners.

Originally posted here:

Progress Releases Kendo UI Builder 2.0, Delivering the New Face of OpenEdge Web Experience - Business Wire (press release)

Posted in Progress | Comments Off on Progress Releases Kendo UI Builder 2.0, Delivering the New Face of OpenEdge Web Experience – Business Wire (press release)